COMPANY INTELLIGENCEWhat the linked records show
MedtechLedger currently links 3 FDA records to the applicant name Beaver-Visitec International, Inc.. It includes 1 original PMA approval. 1 entry is a PMA supplement. 1 entry is a 30-day notice. These are records held by this publication, rather than a count of the company’s entire portfolio.
The dated entries run from Sep 10, 2025 to Oct 27, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.
Product code HQL appears in 3 of the 3 linked filings. The collection spans 1 FDA product code and 1 original PMA application family. These figures describe the filings available here; they do not establish the company’s total device sales or market share.
The largest PMA family in this collection is P240038, with 3 linked entries. Follow the parent application and its dated supplements to distinguish the original device scope from later changes. 2 linked filings have a current plain-language explanation checked against the recorded FDA decision.
Applicant mailing address recorded by FDA: 500 Totten Pond Rd., Waltham, MA, 02451. Recorded on P240038/S004, decision dated Oct 27, 2026.
Device categories in this collection
Intraocular Lens.
Changes described in PMA records
FDA recorded a 30-Day Notice decision, OK30, dated 2026-10-27 for P240038/S004, a supplement to the FINEVISION HP Trifocal IOLs application held by Beaver Visitec International, Inc. The supplement type is a 30-Day Notice and the recorded reason is a process change affecting manufacturer, sterilizer, packager or supplier. The product is an intraocular lens in the Ophthalmic specialty under product code HQL.
The recorded statement describes a high-throughput optical inspection workflow for routine production of these trifocal intraocular lenses, using existing optical metrology integrated with lens-handling and automated data-processing systems. This entry covers the manufacturing process change only; it is not a new approval of the whole lens system. The source lists no supporting documents, so the inspection specifications, validation data and any effect on finished-device characteristics remain unknown.
Whether the change alters clinical performance or labeling cannot be determined from the available record, and no such conclusion is drawn here.
FDA approval-order wording
a high-throughput optical inspection workflow in routine production of FINEVISION HP Trifocal Intraocular Lenses using existing optical metrologer integrated with lens-handling and automated data-processing systems
Oct 27, 2026 · 30-Day NoticeThe FDA database lists decision APPR dated 2026-09-25 for P240038/S003, a Real-Time Process supplement to the FINEVISION HP Trifocal intraocular lens PMA filed by Beaver Visitec International, Inc. The supplement reason is recorded as "Labeling Change - Indications/instructions/shelf life/tradename," and the recorded specialty is Ophthalmic under product code HQL. The supplement number establishes this as a change to the existing P240038 PMA rather than a new approval of the whole lens system.
The reported statement covers an extension of device shelf life from 3 years to 5 years and an expanded storage condition range to 2-35°C. Beyond those two labeling parameters, the supplied fields do not describe the original PMA scope, the prior storage range, or the evidence supporting the change, so the basis for the decision cannot be assessed from this record. The statement documents a reported purpose only and does not establish safety or clinical effectiveness.
FDA approval-order wording
approval for an extension of the device shelf life from 3 years to 5 years, and expanded storage condition range to 2-35°C, for the FINEVISION HP Trifocal intraocular lens.
Sep 25, 2026 · Real-Time ProcessFDA’s recorded scope: Approval for the FINEVISION HP Trifocal Intraocular Lens (IOL). The FlNEVISION HP Trifocal intraocular Lens is indicated for primary implantation in the capsular bag in the posterior chamber of the eye for the visual correction of aphakia in adult patients, with less than 1 diopter of pre-existing corneal astigmatism, in whom a cataractous lens has been removed by phacoemulsification. The lens mitigates the effects of presbyopia by providing improved intermediate and near visual acuity, while maintaining comparable distance visual acuity compared to a monofocal IOL.
Sep 10, 2025Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.